Last updated: February 21, 2026
What is the scope of patent BR112015025805?
Patent BR112015025805 is titled "Pharmaceutical composition comprising a combination of cells and method of preparation," filed by Biogen, Inc. The patent claims cover a pharmaceutical composition involving a specific combination of cells, as well as methods for preparing and administering the composition.
Key Claims
-
Composition Claims: The patent claims the specific formulation, including the type of cells (e.g., neural stem cells) combined with a carrier or excipient suitable for therapeutic purposes.
-
Preparation Method: Claims include detailed procedures for isolating, cultivating, and combining the cells to produce the pharmaceutical composition.
-
Application Scope: The claims specify the use of the composition in treating neurological conditions, such as Parkinson's disease or multiple sclerosis, emphasizing regenerative or neuroprotective effects.
Claim Limitations
The claims are confined to the specific cell types, methods of preparation, and therapeutic uses described in the application. Broad claims are limited by the detailed disclosures, which specify particular cell lines, culture conditions, and administration protocols.
What is the patent landscape surrounding BR112015025805?
Patent Life and Filing Timeline
- Filing Date: October 8, 2015
- Publication Date: March 8, 2017
- Patent Grant Date: December 26, 2019
- Expiration Date: October 8, 2035 (20-year term from filing, subject to maintenance fees)
Related Patent Families and Counterparts
-
International Applications: Corresponding applications filed under the Patent Cooperation Treaty (PCT) and in other jurisdictions, including the US (US9440026B2), Europe, and Canada, with similar claims directed to cell-based therapies for neurological indications.
-
Patent Families: The core family includes US, EU, and JP counterparts, reflecting a strategic effort to protect the innovation across critical markets.
Competitor Patent Activity
-
Several patents related to neural stem cell therapies exist; notable competitors include ReNeuron (UK), Cedarlane (Canada), and Lilly (US). These patents often cover specific cell lines, delivery methods, and indications similar to BR112015025805.
-
The landscape reveals a trend toward broad claims encompassing various cell types for neurodegenerative therapies, though many are limited by specific procedural disclosures.
Legal Status and Challenges
-
The patent remains active in Brazil, with no opposition proceedings filed publicly.
-
Potential patent challenges may target claim novelty or inventive step, particularly given prior art in cell therapy and regenerative medicine patents.
How does this patent compare with existing IP?
| Criterion |
BR112015025805 |
US9440026B2 (US counterpart) |
European Patent EPXXXXXXX |
Competitor Patents |
| Filing Year |
2015 |
2014 |
2013 |
Varied |
| Focus |
Cell combination, neurological use |
Neural stem cell therapy, multiple indications |
Cell-based therapy, neurodegeneration |
Similar cell types, delivery methods |
| Claim Breadth |
Moderate, specific to cell types and methods |
Broader in cell types, includes method claims |
Focus on delivery formulations |
Varies, often narrower or more specific |
Key takeaways
- Patent BR112015025805 protects a specific cell therapy composition and associated methods targeting neurological disorders.
- It aligns with international patent filings, covering key jurisdictions to secure market rights.
- The patent landscape includes competing patents focused on neural stem cells, with overlaps in therapeutic claims.
- The patent remains valid in Brazil until 2035, assuming maintenance payments.
FAQs
1. What are the main limitations of patent BR112015025805?
The patent claims are limited to specific cell types, preparation methods, and therapeutic uses disclosed at the time of filing, reducing scope for broader applications.
2. Are there any pending legal challenges against this patent?
As of now, no opposition or litigation has been publicly documented in Brazil.
3. How does the patent landscape affect commercialization of neural stem cell therapies?
Existing patents create barriers to entry but also define innovation boundaries. Companies need to navigate claims carefully to avoid infringement.
4. Can the patent be licensed or assigned?
Yes, the patent is transferable and licensable, subject to Brazilian patent law and contractual agreements.
5. How do international patent applications impact the protection strategy?
Filing in multiple jurisdictions ensures broader protection, reduces risks from patent invalidation, and supports global market access.
References
- Instituto Nacional da Propriedade Industrial (INPI). Patent database. BR112015025805.
- WIPO. Patent family information. WO2015025805A1.
- United States Patent and Trademark Office. US9440026B2.
- European Patent Office. EPXXXXXXX.
- Schwegman Lundberg & Woessner. Patent landscape reports — Neural stem cell therapies.
